Lowell Anthony1, Aaron I Vinik. 1. Division of Hematology/Oncology, Louisiana State University, New Orleans, LA 70112, USA. lantho@lsuhsc.edu
Abstract
OBJECTIVE: This retrospective study evaluated physician practice patterns in the medical management of patients with neuroendocrine tumors (NETs) treated with octreotide LAR. METHODS: Data were collected from the medical charts of 392 patients diagnosed with NET and treated with octreotide LAR for 4 months or longer. RESULTS: Approximately 72% (n = 284) of patients had metastatic disease with carcinoid syndrome (CS). Of these, 92% (n = 260) had CS at diagnosis and 8% (n = 24) developed CS after diagnosis. Of the patients studied, 89% received octreotide LAR, and the most common octreotide LAR doses were 30 mg (45% of all regimens), 20 mg (32%), and 40 mg (11%). After 12 months of treatment with octreotide LAR, symptom resolution or improvement was seen in 60%, 48%, 48%, and 30% of patients with flushing, diarrhea, bronchoconstriction, and carcinoid heart disease, respectively. Approximately 57% of patients treated with octreotide LAR demonstrated stable disease; with rates of 57% at 20 mg, 57% at 30 mg, 55% at 40 mg, and 50% at 60 mg. CONCLUSIONS: This retrospective study has added to the wealth of evidence demonstrating the efficacy and safety of octreotide LAR in the treatment of patients with NET. The review highlights the importance of regular patient monitoring and clinical management.
OBJECTIVE: This retrospective study evaluated physician practice patterns in the medical management of patients with neuroendocrine tumors (NETs) treated with octreotideLAR. METHODS: Data were collected from the medical charts of 392 patients diagnosed with NET and treated with octreotideLAR for 4 months or longer. RESULTS: Approximately 72% (n = 284) of patients had metastatic disease with carcinoid syndrome (CS). Of these, 92% (n = 260) had CS at diagnosis and 8% (n = 24) developed CS after diagnosis. Of the patients studied, 89% received octreotideLAR, and the most common octreotideLAR doses were 30 mg (45% of all regimens), 20 mg (32%), and 40 mg (11%). After 12 months of treatment with octreotideLAR, symptom resolution or improvement was seen in 60%, 48%, 48%, and 30% of patients with flushing, diarrhea, bronchoconstriction, and carcinoid heart disease, respectively. Approximately 57% of patients treated with octreotideLAR demonstrated stable disease; with rates of 57% at 20 mg, 57% at 30 mg, 55% at 40 mg, and 50% at 60 mg. CONCLUSIONS: This retrospective study has added to the wealth of evidence demonstrating the efficacy and safety of octreotideLAR in the treatment of patients with NET. The review highlights the importance of regular patient monitoring and clinical management.
Authors: Michael S Broder; David Beenhouwer; Jonathan R Strosberg; Maureen P Neary; Dasha Cherepanov Journal: World J Gastroenterol Date: 2015-02-14 Impact factor: 5.742
Authors: Rosaria M Ruggeri; Barbara Altieri; Erika Grossrubatcher; Roberto Minotta; Maria Grazia Tarsitano; Virginia Zamponi; Andrea MIsidori; Antongiulio Faggiano; Anna Maria Colao Journal: Rev Endocr Metab Disord Date: 2022-03-16 Impact factor: 6.514
Authors: David L Chan; Diego Ferone; Manuela Albertelli; Nick Pavlakis; Eva Segelov; Simron Singh Journal: Endocrine Date: 2017-07-19 Impact factor: 3.633
Authors: Jonathan R Strosberg; Al B Benson; Lynn Huynh; Mei Sheng Duh; Jamie Goldman; Vaibhav Sahai; Alfred W Rademaker; Matthew H Kulke Journal: Oncologist Date: 2014-08-05